2-Methoxyethyl-18-methoxycoronaridinate

From Infogalactic: the planetary knowledge core
Jump to: navigation, search
2-Methoxyethyl-18-methoxycoronaridinate
220px
Identifiers
PubChem CID: 10070278
ChemSpider 9212214 YesY
Chemical data
Formula C24H32N2O4
Molecular mass 412.521 g/mol
  • COCCOC(=O)C12CC(C4)CN(C2C4CCOC)CCc5c1nc3ccccc35
  • InChI=1S/C24H32N2O4/c1-28-10-8-17-13-16-14-24(23(27)30-12-11-29-2)21-19(7-9-26(15-16)22(17)24)18-5-3-4-6-20(18)25-21/h3-6,16-17,22,25H,7-15H2,1-2H3/t16-,17+,22+,24-/m1/s1 YesY
  • Key:OLFXZBDPKBSIPG-JIQZGXBJSA-N YesY
  (verify)

(–)-2-Methoxyethyl-18-methoxycoronaridinate (ME-18-MC) is a second generation synthetic derivative of ibogaine developed by the research team led by the pharmacologist Stanley D. Glick from the Albany Medical College and the chemist Martin E. Kuehne from the University of Vermont.[1] In animal studies it has shown similar efficacy to the related compound 18-methoxycoronaridine (18-MC) at reducing self-administration of morphine and methamphetamine but with higher potency by weight, showing anti-addictive effects at the equivalent of half the minimum effective dose of 18-MC. Similarly to 18-MC itself, ME-18-MC acts primarily as a selective α3β4 nicotinic acetylcholine antagonist, although it has a slightly stronger effect than 18-MC as an NMDA antagonist, and its effects on opioid receptors are weaker than those of 18-MC at all except the kappa opioid receptor, at which it has slightly higher affinity than 18-MC.[2][3]

See also

References

  1. Stanley D. Glick, Martin E. Kuehne. Ibogamine congeners. US Patent 6211360
  2. Lua error in package.lua at line 80: module 'strict' not found.
  3. Lua error in package.lua at line 80: module 'strict' not found.